Sorafenib Tosylate is a novel multi-target anticancer drugs, can act simultaneously on tumor cells and tumor blood vessels. It has a dual anti-tumor effects: either by blocking the RAF / MEK / ERK-mediated cell signaling

Pathway directly inhibit the proliferation of tumor cells, but also by inhibiting VE GF and platelet-derived
Health factor (PD GF) receptors and block the formation of tumor angiogenesis, indirectly inhibit the growth of tumor cells.